乌帕替尼-话题@MedSci

#乌帕替尼#

16篇内容 | 1066人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198625, encodeId=951e2198625d2, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=CGH：乌帕替尼在诱导治疗的第一周内减轻克罗恩病症状, objectType=article, longId=821742, objectId=bf48821e42fe, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/abdominal-pain-s2a-photo-of-pain-area-and-internal-abdominal-organs.jpg, objectUrl=/article/show_article.do?id=bf48821e42fe, replyNumber=0, likeNumber=11, createdTime=2024-04-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bf48821e42fe, moduleTitle=CGH：乌帕替尼在诱导治疗的第一周内减轻克罗恩病症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf48821e42fe)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175417, encodeId=e2fb21e541750, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a> <a href='/topic/show?id=e408225855a' target=_blank style='color:#2F92EE;'>#中重度溃疡性结肠炎#</a>, objectTitle=APT：乌帕替尼用于中度至重度活动性溃疡性结肠炎患者16周延长诱导和52周维持治疗的疗效和安全性, objectType=article, longId=805486, objectId=aaa080548609, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894056775_4754896.jpeg, objectUrl=/article/show_article.do?id=aaa080548609, replyNumber=0, likeNumber=29, createdTime=2023-12-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aaa080548609, moduleTitle=APT：乌帕替尼用于中度至重度活动性溃疡性结肠炎患者16周延长诱导和52周维持治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaa080548609)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175275, encodeId=273821e5275cf, content=<a href='/topic/show?id=2e6e6e0315d' target=_blank style='color:#2F92EE;'>#炎症性肠病#</a> <a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=CGH：乌帕替尼治疗溃疡性结肠炎和克罗恩病均有效且安全, objectType=article, longId=805316, objectId=d4f08053166b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/abdominal-pain-s8-photo-of-woman-in-pain-day-to-night.jpg, objectUrl=/article/show_article.do?id=d4f08053166b, replyNumber=0, likeNumber=27, createdTime=2023-12-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d4f08053166b, moduleTitle=CGH：乌帕替尼治疗溃疡性结肠炎和克罗恩病均有效且安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4f08053166b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174710, encodeId=f43021e4710a7, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=05c46645ec3' target=_blank style='color:#2F92EE;'>#溃疡性结肠炎#</a> <a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=口服高选择性JAK抑制剂乌帕替尼新增溃疡性结肠炎和克罗恩病适应症进入医保新目录, objectType=article, longId=804578, objectId=1fd88045e848, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894056775_4754896.jpeg, objectUrl=/article/show_article.do?id=1fd88045e848, replyNumber=0, likeNumber=37, createdTime=2023-12-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1fd88045e848, moduleTitle=口服高选择性JAK抑制剂乌帕替尼新增溃疡性结肠炎和克罗恩病适应症进入医保新目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fd88045e848)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2165528, encodeId=b53b2165528d6, content=两种维持剂量的<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>在中度至重度活动性<a href='/topic/show?id=05c46645ec3' target=_blank style='color:#2F92EE;'>#溃疡性结肠炎#</a>患者中显示出积极的获益-风险特征。乌帕替尼代表了这一人群的有效治疗选择。从目前来看乌帕替尼仍然是优选! 同时，小剂量乌帕替尼也许就已足够!!或小剂量乌帕替尼配合传统的一些小分子化学药物，也应该有不错的效果，这样一方面可以节约治疗费用，另一方面也可以减少乌帕替尼的副作用。, objectTitle=Lancet子刊：乌帕替尼维持治疗对 8 周诱导治疗有应答的中重度活动性UC患者的疗效和安全性, objectType=article, longId=798279, objectId=3f1be982793d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20231023/682e8f53563343d09c78ae8f303aae7f.jpg, objectUrl=/article/show_article.do?id=3f1be982793d, replyNumber=0, likeNumber=39, createdTime=2023-10-29, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=3f1be982793d, moduleTitle=Lancet子刊：乌帕替尼维持治疗对 8 周诱导治疗有应答的中重度活动性UC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f1be982793d)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=2163755, encodeId=0f7c2163e5509, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>治疗中度至重度活动性<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a>患者的内镜和临床效果, objectTitle=第31届欧洲消化疾病周（UEGW） 2023：乌帕替尼治疗中度至重度活动性克罗恩病患者的内镜和临床效果, objectType=article, longId=796946, objectId=f0fce96946e7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301019/1697704737520_92910.png, objectUrl=/article/show_article.do?id=f0fce96946e7, replyNumber=0, likeNumber=34, createdTime=2023-10-19, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f0fce96946e7, moduleTitle=第31届欧洲消化疾病周（UEGW） 2023：乌帕替尼治疗中度至重度活动性克罗恩病患者的内镜和临床效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0fce96946e7)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2115223, encodeId=8beb211522373, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>治疗<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>、<a href='/topic/show?id=5a64966325c' target=_blank style='color:#2F92EE;'>#银屑病关节炎#</a>、<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a>和<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>的安全性分析, objectTitle=RMD Open：乌帕替尼治疗类风湿性关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎的安全性分析, objectType=article, longId=759739, objectId=d72fe597398d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221115/1668549624602_4754896.webp, objectUrl=/article/show_article.do?id=d72fe597398d, replyNumber=0, likeNumber=89, createdTime=2023-02-18, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d72fe597398d, moduleTitle=RMD Open：乌帕替尼治疗类风湿性关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d72fe597398d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2092595, encodeId=f36b2092595c7, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>乌帕替尼, objectTitle=乌帕替尼, objectType=topic, longId=23345, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=27, createdTime=2022-10-09, rootId=0, userName=ms6000001326265410, userId=3ad56519030, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418846, encodeId=acd814188466e, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=JAAD：乌帕替尼治疗中至重度特应性皮炎患者出现痤疮的特征分析, objectType=article, longId=731284, objectId=cb3fe312847f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3fe312847f, replyNumber=0, likeNumber=57, createdTime=2022-07-06, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3fe312847f, moduleTitle=JAAD：乌帕替尼治疗中至重度特应性皮炎患者出现痤疮的特征分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3fe312847f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418845, encodeId=5904141884570, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=JIACI：乌帕替尼治疗重症特应性皮炎的临床研究, objectType=article, longId=729769, objectId=6236e29769f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6236e29769f5, replyNumber=0, likeNumber=0, createdTime=2022-06-18, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6236e29769f5, moduleTitle=JIACI：乌帕替尼治疗重症特应性皮炎的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6236e29769f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418844, encodeId=1f3e141884496, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=J Allergy Clin Immunol：乌帕替尼+局部皮质激素可有效治疗特应性皮炎，效果至少持续52周, objectType=article, longId=723900, objectId=8ba5e23900f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ba5e23900f9, replyNumber=0, likeNumber=43, createdTime=2022-04-11, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ba5e23900f9, moduleTitle=J Allergy Clin Immunol：乌帕替尼+局部皮质激素可有效治疗特应性皮炎，效果至少持续52周, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ba5e23900f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418842, encodeId=28a61418842e5, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代, objectType=article, longId=301171, objectId=e9013011e197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9013011e197, replyNumber=0, likeNumber=37, createdTime=2022-03-21, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9013011e197, moduleTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9013011e197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418841, encodeId=8c8b1418841cf, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性, objectType=article, longId=301032, objectId=aa2b30103219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2b30103219, replyNumber=0, likeNumber=41, createdTime=2022-03-19, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2b30103219, moduleTitle=JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa2b30103219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418840, encodeId=7b7514188402c, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, objectType=article, longId=299190, objectId=b29229919036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29229919036, replyNumber=0, likeNumber=55, createdTime=2022-02-21, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29229919036, moduleTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29229919036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418843, encodeId=e5bf14188434c, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代！, objectType=article, longId=298947, objectId=140429894ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=140429894ed8, replyNumber=0, likeNumber=61, createdTime=2022-02-18, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=140429894ed8, moduleTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=140429894ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418839, encodeId=c5d714188396b, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=Ann Rheum Dis：接受乌帕替尼治疗的类风湿性关节炎患者带状疱疹发病率和危险因素, objectType=article, longId=218375, objectId=d1792183e5ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1792183e5ae, replyNumber=0, likeNumber=49, createdTime=2021-10-12, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1792183e5ae, moduleTitle=Ann Rheum Dis：接受乌帕替尼治疗的类风湿性关节炎患者带状疱疹发病率和危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1792183e5ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418838, encodeId=3fcb14188383b, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=Ann Rheum Dis：类风湿性关节炎换用阿达木单抗或乌帕替尼治疗的疗效和安全性, objectType=article, longId=208557, objectId=2da320855e15, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2da320855e15, replyNumber=0, likeNumber=47, createdTime=2021-03-19, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2da320855e15, moduleTitle=Ann Rheum Dis：类风湿性关节炎换用阿达木单抗或乌帕替尼治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2da320855e15)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418837, encodeId=9cd4141883e7a, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=Ann Rheum Dis：使用乌帕替尼治疗类风湿性关节炎的安全性, objectType=article, longId=207551, objectId=9eac20e551fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eac20e551fd, replyNumber=0, likeNumber=51, createdTime=2021-02-26, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eac20e551fd, moduleTitle=Ann Rheum Dis：使用乌帕替尼治疗类风湿性关节炎的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eac20e551fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=Ann Rheum Dis：乌帕替尼治疗类风湿性关节炎的安全性, objectType=article, longId=203275, objectId=aa6f2032e594, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6f2032e594, replyNumber=0, likeNumber=51, createdTime=2020-11-13, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6f2032e594, moduleTitle=Ann Rheum Dis：乌帕替尼治疗类风湿性关节炎的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6f2032e594)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1418835, encodeId=ee2b141883563, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, objectTitle=乌帕替尼获突破性疗法认定, objectType=article, longId=128339, objectId=314a1283390e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=314a1283390e, replyNumber=0, likeNumber=41, createdTime=2018-02-01, rootId=0, userName=wodejia-dayu, userId=46123431463, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=314a1283390e, moduleTitle=乌帕替尼获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=314a1283390e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

乌帕替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #乌帕替尼#

CGH：乌帕替尼在诱导治疗的第一周内减轻克罗恩病症状

2024-04-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乌帕替尼# #中重度溃疡性结肠炎#

APT：乌帕替尼用于中度至重度活动性溃疡性结肠炎患者16周延长诱导和52周维持治疗的疗效和安全性

2023-12-17发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#炎症性肠病# #乌帕替尼#

CGH：乌帕替尼治疗溃疡性结肠炎和克罗恩病均有效且安全

2023-12-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #溃疡性结肠炎# #乌帕替尼#

口服高选择性JAK抑制剂乌帕替尼新增溃疡性结肠炎和克罗恩病适应症进入医保新目录

2023-12-13发表于上海

(审核中...)

前往app查看评论内容

全文收起两种维持剂量的#乌帕替尼#在中度至重度活动性#溃疡性结肠炎#患者中显示出积极的获益-风险特征。乌帕替尼代表了这一人群的有效治疗选择。从目前来看乌帕替尼仍然是优选! 同时，小剂量乌帕替尼也许就已足够!!或小剂量乌帕替尼配合传统的一些小分子化学药物，也应该有不错的效果，这样一方面可以节约治疗费用，另一方面也可以减少乌帕替尼的副作用。

Lancet子刊：乌帕替尼维持治疗对 8 周诱导治疗有应答的中重度活动性UC患者的疗效和安全性

2023-10-29发表于威斯康星

(审核中...)

前往app查看评论内容

#乌帕替尼#治疗中度至重度活动性#克罗恩病#患者的内镜和临床效果

第31届欧洲消化疾病周（UEGW） 2023：乌帕替尼治疗中度至重度活动性克罗恩病患者的内镜和临床效果

2023-10-19发表于上海

showtest (审核中...)

前往app查看评论内容

#乌帕替尼#治疗#类风湿性关节炎#、#银屑病关节炎#、#强直性脊柱炎#和#特应性皮炎#的安全性分析

RMD Open：乌帕替尼治疗类风湿性关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎的安全性分析

2023-02-18发表于上海

ms6000001326265410 (审核中...)

前往app查看评论内容

#乌帕替尼#乌帕替尼

2022-10-09

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

JAAD：乌帕替尼治疗中至重度特应性皮炎患者出现痤疮的特征分析

2022-07-06

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

JIACI：乌帕替尼治疗重症特应性皮炎的临床研究

2022-06-18

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

J Allergy Clin Immunol：乌帕替尼+局部皮质激素可有效治疗特应性皮炎，效果至少持续52周

2022-04-11

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代

2022-03-21

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性

2022-03-19

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎

2022-02-21

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代！

2022-02-18

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

Ann Rheum Dis：接受乌帕替尼治疗的类风湿性关节炎患者带状疱疹发病率和危险因素

2021-10-12

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

Ann Rheum Dis：类风湿性关节炎换用阿达木单抗或乌帕替尼治疗的疗效和安全性

2021-03-19

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

Ann Rheum Dis：使用乌帕替尼治疗类风湿性关节炎的安全性

2021-02-26

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

Ann Rheum Dis：乌帕替尼治疗类风湿性关节炎的安全性

2020-11-13

wodejia-dayu (审核中...)

前往app查看评论内容

#乌帕替尼#

乌帕替尼获突破性疗法认定

2018-02-01

科室
- - 订阅+
  - 更多科室
工具
服务